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In this issue of Cancer Cell, Park et al. demonstrate that anti-erbB2 antibody primes adaptive immunity for
increased tumor clearance and suggest that chemotherapy may in fact interfere with this process.HER2 (also known as ErbB2 or neu)
activates several pr-survival signaling
pathways and is overexpressed in
approximately 20%–30% of invasive
breast cancers. Breast cancer patients
who have HER2+ breast cancer have
a decreased overall survival compare to
those who do not. Trastuzumab (Hercep-
tin) is a humanized monoclonal antibody
(mAb) that binds the extracellular juxta-
membrane domain of HER2 and has
proved to be an effective treatment of
HER2+ breast cancer. Blockade of HER2
oncogenic signaling and chemosensitiza-
tion have been proposed as the central
mechanisms responsible for the initial
clinical response of HER2+ tumors treated
with Trastuzumab plus chemotherapy
(Hudis, 2007; Moasser, 2007). Trastuzu-
mab is also believed to mediate some of
its therapeutic effect through the recruit-
ment of Fc receptor (FcR)-expressing
immune cells such as monocytes and
natural killer (NK) cells (Clynes et al.,
2000; Musolino et al., 2008).
Correlative evidence has additionally
supported that antibody-dependent cel-
lular cytotoxicity (ADCC) may play amajor
role in the anti-tumor effects of mono-
clonal antibodies such as Trastuzumab
and Rituximab. Consistently, an increase
of tumor-infiltrating leukocytes (TIL),
especially FcR+ cells such as NK cells,
has been observed in tumor tissue after
mAb treatment (Arnould et al., 2006; Var-
chetta et al., 2007), and patients respond-
ing to mAb treatment had higher in situ
infiltration of leukocytes and an increased
capacity to mediate in vitro ADCC activ-
ity (Gennari et al., 2004). While innate
immune responses have been suggested
to be instrumental to mAb cancer thera-
pies, xenograft models used for preclin-
ical evaluation of mAbs traditionally failed
to account for adaptive immunity. Several
ErbB2 transgenic mousemammary tumormodels have been developed based
on expression of oncogenic rat ErbB2.
Importantly, tumors can be harvested
and transplanted back into immunocom-
petent hosts for therapeutic analysis.
Park et al. now extend previous findings
in mice to demonstrate that the mecha-
nisms of tumor regression by anti-ErbB2
mAb therapy also require host danger
signals, Toll-like receptor signaling, and
an adaptive immune response (Park
et al., 2010). They showed that the mouse
anti-rat ErbB2 mAb 7.16.4 required host
FcR and, at least in part, HMGB-1,
MyD88 signaling, CD8a+, cells and
adaptive (RAG-dependent) immunity to
mediate its optimal effect. HMGB-1 is an
abundant nuclear DNA binding protein
that acts as an immunogenic stimulator
when released in the extracellular milieu
by necrotic and inflammatory cells. Extra-
cellular HMGB-1 binds its receptor RAGE
on antigen-presenting cells (APC) and
may signal the neighboring cells for tis-
sue damage. Their data together sug-
gested a pathway whereby FcR-depen-
dent ADCC and/or ErbB2 signaling
blockade causes tumor cell death and
the release of danger signals, such as
HMGB-1, that trigger an innate MyD88-
dependent pathway in APC (Figure 1).
Park et al. postulate that APC might also
use FcR to internalize antigens based on
the finding from several previous studies
showing that anti-tumor antibody treat-
ment enhances cross-priming of CD8+
T cells through FcR-mediated phagocy-
tosis and immune complex formation
(Dhodapkar et al., 2002). However, the
Park et al. study did not enumerate
tumor-specific T cells or use an antigen
or more specific deficiencies of CD8a+
DC or CD8ab+ T cells to fully explore the
role of cross-priming in the generation of
T cells specific to the tumor. It is also
unclear what role ADCC plays and whatCancer Cell 18might be the key signals from cells
attacked in the initial assault that primes
adaptive immunity. Although Park et al.
show an increase in the tumor infiltration
of CD8+ cells and interferon-g in lymphoid
tissue of mice treated with anti-ErbB2
mAb, it remains unclear whether these
events are linked and what the immune
effector mechanisms that reduce the
growth of the initial and rechallenged
tumors are. These findings in mice were
supported by increased TIL detected
in a small number of HER2+ breast can-
cer patients after treatment with chemo-
therapy plus Trastuzumab, but not in
HER2 breast cancer patients treated
with chemotherapy alone. However, fur-
ther supporting clinical data are needed.
The appropriate comparison here would
have been among all HER2+ breast
cancers treated with or without Trastuzu-
mab because the main issue here relates
to Trastuzumab treatment, not HER2+
versus HER2 breast cancer. Further-
more, ER+/HER2 tumors are less likely
to have TILs pre- and post-therapy. Since
few, if any, patients are treated with Tras-
tuzumab alone, the definitive role of adap-
tive immunity in the anticancer activity of
Trastuzumab and similar mAbs in humans
will require specialized controlled trials.
It has long been suspected that chemo-
therapies may be immunosuppressive,
but recently it has been shown that
some chemotherapies can kill tumor cells
in a manner that activates the NLRP3
inflammasome in APC, which primes
tumor-specific adaptive immunity via
IL-1b (Ghiringhelli et al., 2009). Park et al.
describe results from mouse experiments
that suggest that paclitaxel or cyclophos-
phamide administered shortly after anti-
ErbB2 mAb may dramatically interfere
with the tumor-specific memory gener-
ated by anti-ErbB2 mAbs (Figure 1).
Collectively, this work makes it very clear, August 17, 2010 ª2010 Elsevier Inc. 101
Figure 1. A Revised Mechanism of Action for Trastuzumab
The study by Park et al. proposes that tumor cell death induced by anti-ErbB2
monoclonal antibody (mAb) therapy causes the release of danger signals such
as HMGB-1, triggers MyD88-dependent activation of antigen-presenting cells
(APC), and generates CD8a-dependent adaptive anti-tumor immunity.
Park et al. (2010) observed that paclitaxel (PTX) administration after anti-
ErbB2 mAb abrogated secondary immune responses to tumor, while it
preserved immune protection if administered 24 hr before anti-ErbB2 mAb.
(1), Blocking of oncogenic signals; (2), FcRg-dependent activation of innate
immune cells; (3), HMGB-1-dependent and MyD88-dependent activation of
APC; (4), Activation of CD8a-dependent adaptive anti-tumor immunity.
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Previewsthat the dose, timing, and
effects of all first line thera-
peutics that directly or indi-
rectly prime tumor-specific
immunity need careful atten-
tion. The issue of what
approach to take with trastu-
zumab refractory disease is
complicated, however, so
caution should be taken in
not overinterpreting these
findings. The data from Park
et al. does not explain why
Trastuzumab in combina-
tion with chemotherapy is
active even after progression
on Trastuzumab. Regard-
less, chemotherapy sched-
uling could have an impact
in some people treated with
Trastuzumab, but to optimize
the clinical efficacy would
require somemajor rethinking
of clinical trial design in these
patients. Clearly, TILs are
an independent predictor ofresponse to neoadjuvant chemotherapy
in breast cancer (Denkert et al., 2010),
so more large studies of effective breast
cancer therapies need to more rigorously
assess the importance of immune mole-
cules and pathways in therapeutic
outcomes.
The current work also raises the
interesting possibility that alternative
combination strategies may be used to
capitalize on the adaptive tumor-spe-
cific immunity generated by anti-ErbB2
mAbs. Using intratumoral delivery of an
adenovirus-LIGHT construct that report-
edly increases adhesion and attraction
of TIL, Park et al. observed dramatically
improved anti-ErbB2 anti-tumor activity,
but no clear mechanism studies were pre-
sented to support how best to use the102 Cancer Cell 18, August 17, 2010 ª2010 Estrategy. Nevertheless, immunothera-
peutic approaches in late-phase clinical
trials that enhance CD8+ T cell anti-tumor
activity, such as anti-CTLA4 or anti-PD1
mAb, or a cancer vaccine, might be inter-
esting in combinationwith Trastuzumab in
these mousemodels and eventually in the
clinic. Although ErbB2-targeted therapy
using Trastuzumab constitutes a major
advance in the treatment of ErbB2+ breast
cancer, there remains an unmet medical
need for patients who are on adjuvant
Trastuzumab but develop metastatic
disease. The Park et al. study illustrates
one avenue to improve outcomes and
importantly cautions rational combination
therapies that are only based on the
intrinsic activity of these agents upon the
tumor and not the host immunity.lsevier Inc.ACKNOWLEDGMENTS
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